EntryPoint Capital LLC bought a new position in Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Free Report) in the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 8,872 shares of the biopharmaceutical company's stock, valued at approximately $298,000.
Other large investors also recently added to or reduced their stakes in the company. Northern Trust Corp grew its position in Xenon Pharmaceuticals by 51.6% in the fourth quarter. Northern Trust Corp now owns 65,783 shares of the biopharmaceutical company's stock worth $2,579,000 after acquiring an additional 22,377 shares in the last quarter. Ameriprise Financial Inc. grew its position in Xenon Pharmaceuticals by 39.1% in the fourth quarter. Ameriprise Financial Inc. now owns 92,350 shares of the biopharmaceutical company's stock worth $3,620,000 after acquiring an additional 25,967 shares in the last quarter. Mutual of America Capital Management LLC bought a new stake in Xenon Pharmaceuticals in the first quarter worth approximately $1,636,000. Natixis Advisors LLC grew its position in Xenon Pharmaceuticals by 1.9% in the first quarter. Natixis Advisors LLC now owns 24,010 shares of the biopharmaceutical company's stock worth $806,000 after acquiring an additional 456 shares in the last quarter. Finally, Bank of New York Mellon Corp grew its position in Xenon Pharmaceuticals by 439.0% in the first quarter. Bank of New York Mellon Corp now owns 251,147 shares of the biopharmaceutical company's stock worth $8,426,000 after acquiring an additional 204,550 shares in the last quarter. 95.45% of the stock is owned by institutional investors.
Wall Street Analyst Weigh In
Several analysts have commented on XENE shares. William Blair reissued an "outperform" rating on shares of Xenon Pharmaceuticals in a research report on Monday, May 5th. HC Wainwright reaffirmed a "buy" rating and set a $53.00 price objective on shares of Xenon Pharmaceuticals in a report on Tuesday, May 13th. Evercore ISI began coverage on shares of Xenon Pharmaceuticals in a report on Wednesday, May 14th. They set an "outperform" rating and a $55.00 price objective for the company. Chardan Capital reaffirmed a "buy" rating and set a $55.00 price objective on shares of Xenon Pharmaceuticals in a report on Tuesday, August 12th. Finally, Wedbush upped their price objective on shares of Xenon Pharmaceuticals from $42.00 to $43.00 and gave the stock an "outperform" rating in a report on Tuesday, August 12th. Eleven investment analysts have rated the stock with a Buy rating, According to MarketBeat, the stock has an average rating of "Buy" and a consensus target price of $53.20.
Check Out Our Latest Stock Analysis on XENE
Xenon Pharmaceuticals Stock Performance
Shares of XENE stock traded up $0.24 during mid-day trading on Wednesday, reaching $38.89. The company's stock had a trading volume of 241,643 shares, compared to its average volume of 889,180. Xenon Pharmaceuticals Inc. has a 1-year low of $26.74 and a 1-year high of $46.00. The company has a market cap of $3.00 billion, a P/E ratio of -10.95 and a beta of 1.16. The firm's 50-day moving average is $33.42 and its two-hundred day moving average is $33.93.
Xenon Pharmaceuticals (NASDAQ:XENE - Get Free Report) last announced its quarterly earnings data on Monday, August 11th. The biopharmaceutical company reported ($1.07) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.03) by ($0.04). During the same quarter in the prior year, the business posted ($0.75) EPS. Sell-side analysts anticipate that Xenon Pharmaceuticals Inc. will post -3.1 EPS for the current year.
About Xenon Pharmaceuticals
(
Free Report)
Xenon Pharmaceuticals Inc, a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders.
Further Reading
Before you consider Xenon Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Xenon Pharmaceuticals wasn't on the list.
While Xenon Pharmaceuticals currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
MarketBeat All Access